Last reviewed · How we verify
Heterologous mRNA booster vaccine
Heterologous mRNA booster vaccine is a mRNA vaccine Biologic drug developed by Tan Tock Seng Hospital. It is currently FDA-approved for COVID-19 booster vaccination (heterologous prime-boost strategy).
A heterologous mRNA booster vaccine uses messenger RNA from a different pathogen or platform to enhance immune response in individuals previously primed with another vaccine.
A heterologous mRNA booster vaccine uses messenger RNA from a different pathogen or platform to enhance immune response in individuals previously primed with another vaccine. Used for COVID-19 booster vaccination (heterologous prime-boost strategy).
At a glance
| Generic name | Heterologous mRNA booster vaccine |
|---|---|
| Sponsor | Tan Tock Seng Hospital |
| Drug class | mRNA vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Heterologous boosting leverages cross-reactive T-cell and B-cell responses by administering an mRNA vaccine encoding antigens from a different but related pathogen or using a different mRNA platform after initial vaccination. This approach aims to broaden and strengthen adaptive immunity beyond what homologous boosting (same vaccine repeated) can achieve, potentially improving durability and breadth of protection.
Approved indications
- COVID-19 booster vaccination (heterologous prime-boost strategy)
Common side effects
- Injection site pain or swelling
- Fatigue
- Headache
- Myalgia
- Fever
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (PHASE1, PHASE2)
- Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (PHASE2, PHASE3)
- Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC] (PHASE4)
- Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile (PHASE2)
- Adaptive Immune Response to COVID-19 Vaccination
- A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster (PHASE1)
- A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heterologous mRNA booster vaccine CI brief — competitive landscape report
- Heterologous mRNA booster vaccine updates RSS · CI watch RSS
- Tan Tock Seng Hospital portfolio CI
Frequently asked questions about Heterologous mRNA booster vaccine
What is Heterologous mRNA booster vaccine?
How does Heterologous mRNA booster vaccine work?
What is Heterologous mRNA booster vaccine used for?
Who makes Heterologous mRNA booster vaccine?
What drug class is Heterologous mRNA booster vaccine in?
What development phase is Heterologous mRNA booster vaccine in?
What are the side effects of Heterologous mRNA booster vaccine?
Related
- Drug class: All mRNA vaccine drugs
- Manufacturer: Tan Tock Seng Hospital — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for COVID-19 booster vaccination (heterologous prime-boost strategy)
- Compare: Heterologous mRNA booster vaccine vs similar drugs
- Pricing: Heterologous mRNA booster vaccine cost, discount & access